{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T08:19:31Z","timestamp":1793521171340,"version":"4.5.0"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2023,4,8]],"date-time":"2023-04-08T00:00:00Z","timestamp":1680912000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,8]],"date-time":"2023-04-08T00:00:00Z","timestamp":1680912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"DOI":"10.1007\/s40620-023-01590-3","type":"journal-article","created":{"date-parts":[[2023,4,8]],"date-time":"2023-04-08T05:02:40Z","timestamp":1680930160000},"page":"1549-1559","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Relationship between lipoprotein(a) levels, cardiovascular outcomes and death in patients with chronic kidney disease: a systematic review of prospective studies"],"prefix":"10.1093","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3694-1083","authenticated-orcid":false,"given":"Leandro","family":"Barbagelata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Masson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Corral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augusto","family":"Lavalle-Cobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Patricio","family":"Nogueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Rosa Diez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,4,8]]},"reference":[{"key":"1590_CR1","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.atherosclerosis.2018.08.046","volume":"278","author":"AB Reiss","year":"2018","unstructured":"Reiss AB, Miyawaki N, Moon J, Kasselman LJ, Voloshyna I, D\u2019Avino R Jr et al (2018) CKD, arterial calcification, atherosclerosis and bone health: inter-relationships and controversies. Atherosclerosis 278:49\u201359. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.08.046","journal-title":"Atherosclerosis"},{"key":"1590_CR2","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/978-981-19-0394-6_9","volume":"1372","author":"X Pan","year":"2022","unstructured":"Pan X (2022) Cholesterol metabolism in chronic kidney disease: physiology, pathologic mechanisms, and treatment. Adv Exp Med Biol 1372:119\u2013143. https:\/\/doi.org\/10.1007\/978-981-19-0394-6_9","journal-title":"Adv Exp Med Biol"},{"issue":"2","key":"1590_CR3","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1159\/000488816","volume":"46","author":"MC Bulbul","year":"2018","unstructured":"Bulbul MC, Dagel T, Afsar B, Ulusu NN, Kuwabara M, Covic A et al (2018) Disorders of lipid metabolism in chronic kidney disease. Blood Purif 46(2):144\u2013152. https:\/\/doi.org\/10.1159\/000488816","journal-title":"Blood Purif"},{"issue":"9","key":"1590_CR4","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1159\/000518456","volume":"52","author":"P Theoflis","year":"2021","unstructured":"Theoflis P, Vordoni A, Koukoulaki M, Vlachopanos G, Kalaitzidis RG (2021) Dyslipidemia in chronic kidney disease: contemporary concepts and future therapeutic perspectives. Am J Nephrol 52(9):693\u2013701. https:\/\/doi.org\/10.1159\/000518456","journal-title":"Am J Nephrol"},{"issue":"Suppl 1","key":"1590_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11789-017-0086-z","volume":"12","author":"B Hohenstein","year":"2017","unstructured":"Hohenstein B (2017) Lipoprotein(a) in nephrological patients. Clin Res Cardiol Suppl 12(Suppl 1):27\u201330. https:\/\/doi.org\/10.1007\/s11789-017-0086-z","journal-title":"Clin Res Cardiol Suppl"},{"issue":"2020","key":"1590_CR6","doi-asserted-by":"publisher","first-page":"3491764","DOI":"10.1155\/2020\/3491764","volume":"1","author":"MM Jawi","year":"2020","unstructured":"Jawi MM, Frohlich J, Chan SY (2020) Lipoprotein(a) the insurgent: a new insight into the structure, function, metabolism, pathogenicity, and medications affecting lipoprotein(a) molecule. J Lipids 1(2020):3491764. https:\/\/doi.org\/10.1155\/2020\/3491764","journal-title":"J Lipids"},{"key":"1590_CR7","doi-asserted-by":"publisher","DOI":"10.1161\/ATV.0000000000000147","author":"G Reyes-Soffer","year":"2021","unstructured":"Reyes-Soffer G, Ginsberg HN, Berglund L, Duell PB, Heffron SP, Kamstrup PR et al (2021) Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. https:\/\/doi.org\/10.1161\/ATV.0000000000000147","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"1590_CR8","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1172\/JCI115855","volume":"90","author":"E Boerwinkle","year":"1992","unstructured":"Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH (1992) Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest 90(1):52\u201360. https:\/\/doi.org\/10.1172\/JCI115855","journal-title":"J Clin Invest"},{"key":"1590_CR9","first-page":"1099","volume":"8","author":"T Auguet","year":"1993","unstructured":"Auguet T, Senti M, Rubies-Prat J, Pelegri A, Pedro-Botet J, Nogues X et al (1993) Serum lipoprotein(a) concentration in patients with chronic renal failure receiving haemodialysis: Influence of apolipoprotein (a) genetic polymorphism. Nephrol Dial Transpl 8:1099\u20131103","journal-title":"Nephrol Dial Transpl"},{"issue":"2","key":"1590_CR10","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1161\/01.cir.86.2.475","volume":"86","author":"MD Cressman","year":"1992","unstructured":"Cressman MD, Heyka RJ, Paganini EP, O\u2019Neil J, Skibinski CI, Hoff HF (1992) Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation 86(2):475\u2013482. https:\/\/doi.org\/10.1161\/01.cir.86.2.475","journal-title":"Circulation"},{"key":"1590_CR11","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/0009-3084(94)90165-1","volume":"67\u201368","author":"MD Cressman","year":"1994","unstructured":"Cressman MD, Abood D, O\u2019Neil J, Hoff HF (1994) Lp(a) and premature mortality during chronic hemodialysis treatment. Chem Phys Lipids 67\u201368:419\u2013427. https:\/\/doi.org\/10.1016\/0009-3084(94)90165-1","journal-title":"Chem Phys Lipids"},{"key":"1590_CR12","doi-asserted-by":"publisher","first-page":"S251","DOI":"10.1046\/j.1523-1755.1999.07167.x","volume":"71","author":"Y Koda","year":"1999","unstructured":"Koda Y, Nishi S, Suzuki M, Hirasawa Y (1999) Lipoprotein(a) is a predictor for cardiovascular mortality of hemodialysis patients. Kidney Int Suppl 71:S251\u2013S253. https:\/\/doi.org\/10.1046\/j.1523-1755.1999.07167.x","journal-title":"Kidney Int Suppl"},{"issue":"5","key":"1590_CR13","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1681\/ASN.V1051027","volume":"10","author":"F Kronenberg","year":"1999","unstructured":"Kronenberg F, Neyer U, Lhotta K, Trenkwalder E, Auinger M, Pribasnig S et al (1999) The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: a prospective follow-up. J Am Soc Nephrol 10(5):1027\u20131036. https:\/\/doi.org\/10.1681\/ASN.V1051027","journal-title":"J Am Soc Nephrol"},{"key":"1590_CR14","doi-asserted-by":"publisher","first-page":"S242","DOI":"10.1046\/j.1523-1755.1999.07164.x","volume":"71","author":"H Ohashi","year":"1999","unstructured":"Ohashi H, Oda H, Ohno M, Watanabe S, Sakata S (1999) Lipoprotein(a) as a risk factor for coronary artery disease in hemodialysis patients. Kidney Int Suppl 71:S242\u2013S244. https:\/\/doi.org\/10.1046\/j.1523-1755.1999.07164.x","journal-title":"Kidney Int Suppl"},{"issue":"4","key":"1590_CR15","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1177\/089686080202200408","volume":"22","author":"E Iliescu","year":"2002","unstructured":"Iliescu E, Marcovina S, Morton A, Lam M, Koschinsky M (2002) Apolipoprotein(a) phenotype and lipoprotein(a) level predict peritoneal dialysis patient mortality. Perit Dial Int 22(4):492\u2013499","journal-title":"Perit Dial Int"},{"issue":"22","key":"1590_CR16","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1161\/01.cir.0000038946.91899.bb","volume":"106","author":"J Longenecker","year":"2002","unstructured":"Longenecker J, Klag M, Marcovina S, Powe N, Fink N et al (2002) Small apolipoprotein(a) size predicts mortality in end-stage renal disease: the CHOICE study. Circulation 106(22):2812\u20132818. https:\/\/doi.org\/10.1161\/01.cir.0000038946.91899.bb","journal-title":"Circulation"},{"issue":"6","key":"1590_CR17","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1681\/ASN.2004110922","volume":"16","author":"J Longenecker","year":"2005","unstructured":"Longenecker J, Klag M, Marcovina S, Liu YM, Jaar B, Powe N et al (2005) High lipoprotein(a) levels and small apolipoprotein(a) size prospectively predict cardiovascular events in dialysis patients. J Am Soc Nephrol 16(6):1794\u20131802. https:\/\/doi.org\/10.1681\/ASN.2004110922","journal-title":"J Am Soc Nephrol"},{"issue":"14","key":"1590_CR18","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1001\/jama.293.14.1737","volume":"293","author":"M Shlipak","year":"2005","unstructured":"Shlipak M, Fried L, Cushman M, Manolio T, Peterson D, Stehman-Breen C et al (2005) Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA 293(14):1737\u20131745. https:\/\/doi.org\/10.1001\/jama.293.14.1737","journal-title":"JAMA"},{"key":"1590_CR19","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ijcard.2015.12.007","volume":"205","author":"H Konishi","year":"2016","unstructured":"Konishi H, Miyauchi K, Tsuboi S, Ogita M, Naito R, Dohi T et al (2016) Plasma lipoprotein(a) predicts major cardiovascular events in patients with chronic kidney disease who undergo percutaneous coronary intervention. Int J Cardiol 205:50\u201353. https:\/\/doi.org\/10.1016\/j.ijcard.2015.12.007","journal-title":"Int J Cardiol"},{"issue":"11","key":"1590_CR20","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1093\/ndt\/gfv428","volume":"31","author":"B Kollerits","year":"2016","unstructured":"Kollerits B, Drechsler C, Krane V, Lamina C, M\u00e4rz W, Dieplinger H et al (2016) Lipoprotein(a) concentrations, apolipoprotein(a) isoforms and clinical endpoints in haemodialysis patients with type 2 diabetes mellitus: results from the 4D Study. Nephrol Dial Transpl 31(11):1901\u20131908. https:\/\/doi.org\/10.1093\/ndt\/gfv428","journal-title":"Nephrol Dial Transpl"},{"issue":"10","key":"1590_CR21","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1161\/ATVBAHA.117.309920","volume":"37","author":"A Bajaj","year":"2017","unstructured":"Bajaj A, Damrauer S, Anderson A, Xie D, Budoff M, Go A et al (2017) Lipoprotein(a) and risk of myocardial infarction and death in chronic kidney disease: findings from the CRIC study (chronic renal insufficiency cohort). Arterioscler Thromb Vasc Biol 37(10):1971\u20131978. https:\/\/doi.org\/10.1161\/ATVBAHA.117.309920","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1590_CR22","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.atherosclerosis.2022.04.007","volume":"349","author":"Q Li","year":"2022","unstructured":"Li Q, Chen Y, Yu L, Zhu L, Wang Z, Jiao S et al (2022) The relationship between lipoprotein(a) and cardiovascular events in acute coronary syndrome patients with and without chronic kidney disease. Atherosclerosis 349:204\u2013210. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.04.007","journal-title":"Atherosclerosis"},{"issue":"3","key":"1590_CR23","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s11255-021-02919-2","volume":"54","author":"CE Vlad","year":"2022","unstructured":"Vlad CE, Foia L, Pavel-Tanasa M, Toma V, Florea L, Voroneanu L et al (2022) Evaluation of cardiovascular events and progression to end-stage renal disease in patients with dyslipidemia and chronic kidney disease from the North-Eastern area of Romania. Int Urol Nephrol 54(3):647\u2013659. https:\/\/doi.org\/10.1007\/s11255-021-02919-2","journal-title":"Int Urol Nephrol"},{"issue":"9","key":"1590_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0735-1097(22)02502-5","volume":"79","author":"B Poudel","year":"2022","unstructured":"Poudel B, Rosenson RS, Kent S, Bittner V, Gutierrez O et al (2022) Lipoprotein (a) and the risk for atherosclerotic cardiovascular events among adults with chronic kidney disease and a history of atherosclerotic cardiovascular disease. J Am Coll Cardiol 79(9):1\u20133489","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"1590_CR25","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s11255-019-02170-w","volume":"51","author":"C Vlad","year":"2019","unstructured":"Vlad C, Burlacu A, Florea L, Artene B, Badarau S, Covic A et al (2019) A comprehensive review on apolipoproteins as nontraditional cardiovascular risk factors in end-stage renal disease: current evidence and perspectives. Int Urol Nephrol 51(7):1173\u20131189. https:\/\/doi.org\/10.1007\/s11255-019-02170-w","journal-title":"Int Urol Nephrol"},{"issue":"8","key":"1590_CR26","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1001\/jamasurg.2021.0546","volume":"156","author":"S Arya","year":"2021","unstructured":"Arya S, Kaji AH, Boermeester MA (2021) PRISMA reporting guidelines for meta-analyses and systematic reviews. JAMA Surg 156(8):789\u2013790. https:\/\/doi.org\/10.1001\/jamasurg.2021.0546","journal-title":"JAMA Surg"},{"issue":"4","key":"1590_CR27","doi-asserted-by":"publisher","first-page":"280","DOI":"10.7326\/0003-4819-158-4-201302190-00009","volume":"158","author":"JA Hayden","year":"2013","unstructured":"Hayden JA, van der Windt DA, Cartwright JL, C\u00f4t\u00e9 P, Bombardier C (2013) Assessing bias in studies of prognostic factors. Ann Intern Med 158(4):280\u2013286. https:\/\/doi.org\/10.7326\/0003-4819-158-4-201302190-00009","journal-title":"Ann Intern Med"},{"issue":"22","key":"1590_CR28","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1093\/eurheartj\/ehaa1050","volume":"42","author":"T Speer","year":"2021","unstructured":"Speer T, Ridker PM, von Eckardstein A, Schunk SJ, Fliser D (2021) Lipoproteins in chronic kidney disease: from bench to bedside. Eur Heart J 42(22):2170\u20132185. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa1050","journal-title":"Eur Heart J"},{"issue":"4","key":"1590_CR29","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1194\/jlr.R083626","volume":"59","author":"JC Hopewell","year":"2018","unstructured":"Hopewell JC, Haynes R, Baigent C (2018) The role of lipoprotein (a) in chronic kidney disease. J Lipid Res 59(4):577\u2013585. https:\/\/doi.org\/10.1194\/jlr.R083626","journal-title":"J Lipid Res"},{"issue":"2","key":"1590_CR30","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/s0021-9150(99)00014-3","volume":"144","author":"L Kerschdorfer","year":"1999","unstructured":"Kerschdorfer L, K\u00f6nig P, Neyer U, B\u00f6sm\u00fcller C, Lhotta K, Auinger M, Hohenegger M et al (1999) Lipoprotein(a) plasma concentrations after renal transplantation: a prospective evaluation after 4 years of follow-up. Atherosclerosis 144(2):381\u2013391. https:\/\/doi.org\/10.1016\/s0021-9150(99)00014-3","journal-title":"Atherosclerosis"},{"issue":"3","key":"1590_CR31","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/MOL.0000000000000823","volume":"33","author":"MB Boffa","year":"2022","unstructured":"Boffa MB, Koschinsky ML (2022) Understanding the ins and outs of lipoprotein (a) metabolism. Curr Opin Lipidol 33(3):185\u2013192. https:\/\/doi.org\/10.1097\/MOL.0000000000000823","journal-title":"Curr Opin Lipidol"},{"key":"1590_CR32","doi-asserted-by":"publisher","first-page":"105275","DOI":"10.1016\/j.phrs.2020.105275","volume":"163","author":"X Wang","year":"2021","unstructured":"Wang X, Li J, Ju J, Fan Y, Xu H (2021) Effect of different types and dosages of statins on plasma lipoprotein(a) levels: a network meta-analysis. Pharmacol Res 163:105275. https:\/\/doi.org\/10.1016\/j.phrs.2020.105275","journal-title":"Pharmacol Res"},{"key":"1590_CR33","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa1300955","volume":"371","author":"MJ Landray","year":"2014","unstructured":"HPS2-THRIVE Collaborative Group, Landray MJ, Haynes R, Hopewell JC, Parish S, Aung T, Tomson J et al (2014) Effects of extended release niacin with laropiprant in high-risk patients. N Engl J Med 371:203\u2013212. https:\/\/doi.org\/10.1056\/NEJMoa1300955","journal-title":"N Engl J Med"},{"issue":"33","key":"1590_CR34","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1093\/eurheartj\/ehy862","volume":"40","author":"LCA Stiekema","year":"2019","unstructured":"Stiekema LCA, Stroes ESG, Verweij SL, Kassahun H, Chen L, Wasserman SM et al (2019) Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low density lipoprotein cholesterol reduction by proprotein convertase subtilisin\/kexin type 9 antibody treatment. Eur Heart J 40(33):2775\u20132781. https:\/\/doi.org\/10.1093\/eurheartj\/ehy862","journal-title":"Eur Heart J"},{"key":"1590_CR35","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejim.2020.04.036","volume":"76","author":"G Lippi","year":"2020","unstructured":"Lippi G, Favaloro EJ, Sanchis-Gomar F (2020) Antisense lipoprotein [a] therapy: state-of-the-art and future perspectives. Eur J Intern Med 76:8\u201313. https:\/\/doi.org\/10.1016\/j.ejim.2020.04.036","journal-title":"Eur J Intern Med"},{"issue":"3","key":"1590_CR36","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1056\/NEJMoa1905239","volume":"382","author":"S Tsimikas","year":"2020","unstructured":"Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, Tardif JC, Baum SJ, Steinhagen-Thiessen E et al (2020) Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med 382(3):244\u2013255. https:\/\/doi.org\/10.1056\/NEJMoa1905239","journal-title":"N Engl J Med"},{"issue":"5","key":"1590_CR37","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1093\/ckj\/sfaa001","volume":"13","author":"R Fern\u00e1ndez-Prado","year":"2020","unstructured":"Fern\u00e1ndez-Prado R, Perez-Gomez MV, Ortiz A (2020) Pelacarsen for lowering lipoprotein(a): implications for patients with chronic kidney disease. Clin Kidney J 13(5):753\u2013757. https:\/\/doi.org\/10.1093\/ckj\/sfaa001","journal-title":"Clin Kidney J"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-023-01590-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40620-023-01590-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-023-01590-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:52:42Z","timestamp":1777564362000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/36\/6\/1549\/8304213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,8]]},"references-count":37,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["1590"],"URL":"https:\/\/doi.org\/10.1007\/s40620-023-01590-3","relation":{},"ISSN":["1724-6059"],"issn-type":[{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,8]]},"assertion":[{"value":"23 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}}]}}